In HNSCC cells, c-Src was proposed to be a downstream target of the EGFR, as treatment of cells with the EGFR inhibitor ZD1839 was found to block activation of the c-Src pathway (Yang et al, 2004). The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.